The potential to target CCL5/CCR5 in breast cancer
- PMID: 25256399
- DOI: 10.1517/14728222.2014.949238
The potential to target CCL5/CCR5 in breast cancer
Abstract
Introduction: Chemokines play a crucial role in breast cancer tumorigenesis and progression. Recently, the chemokine (C-C motif) ligand 5 (CCL5), which can be secreted either by tumor cells or by mesenchymal stromal cells recruited to the tumor, has been identified as a key node in the bidirectional communication between breast cancer and normal cells.
Areas covered: In this review, the authors discuss the role of CCL5/chemokine receptor 5 (CCR5) axis in promoting breast cancer onset and progression. Interrogation of large clinical databases has demonstrated increased expression of the CCL5/CCR5 axis in specific subtypes of breast cancer. The activation of the receptor CCR5 in breast cancer cells controls their invasiveness serving as a driver for metastasis. Furthermore, the CCL5/CCR5 axis participates in the recruitment of specific immune cells into tumors, inducing local immunosuppression and favoring tumor progression.
Expert opinion: The role of CCR5 in HIV infection led to the development of specific and potent CCR5 antagonists. The data reviewed here includes basic and translational studies that support the use of such CCR5 antagonists in breast cancer patients as adjuvant therapy to block the metastasis.
Keywords: CCL5; breast cancer; chemokine receptor 5; maraviroc; mesenchymal stromal cells; metastasis.
Similar articles
-
CCR5 antagonist blocks metastasis of basal breast cancer cells.Cancer Res. 2012 Aug 1;72(15):3839-50. doi: 10.1158/0008-5472.CAN-11-3917. Epub 2012 May 25. Cancer Res. 2012. PMID: 22637726
-
Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer.Int J Mol Sci. 2018 May 16;19(5):1477. doi: 10.3390/ijms19051477. Int J Mol Sci. 2018. PMID: 29772686 Free PMC article. Review.
-
Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer.Oncotarget. 2016 Dec 20;7(51):85437-85449. doi: 10.18632/oncotarget.13387. Oncotarget. 2016. PMID: 27863423 Free PMC article.
-
Breast Phyllodes Tumors Recruit and Repolarize Tumor-Associated Macrophages via Secreting CCL5 to Promote Malignant Progression, Which Can Be Inhibited by CCR5 Inhibition Therapy.Clin Cancer Res. 2019 Jul 1;25(13):3873-3886. doi: 10.1158/1078-0432.CCR-18-3421. Epub 2019 Mar 19. Clin Cancer Res. 2019. PMID: 30890553
-
Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme.Radiol Oncol. 2019 Nov 20;53(4):397-406. doi: 10.2478/raon-2019-0057. Radiol Oncol. 2019. PMID: 31747383 Free PMC article. Review.
Cited by
-
Undetected Jawbone Marrow Defects as Inflammatory and Degenerative Signaling Pathways: Chemokine RANTES/CCL5 as a Possible Link Between the Jawbone and Systemic Interactions?J Inflamm Res. 2021 Apr 21;14:1603-1612. doi: 10.2147/JIR.S307635. eCollection 2021. J Inflamm Res. 2021. PMID: 33911892 Free PMC article.
-
Role of chemokine systems in cancer and inflammatory diseases.MedComm (2020). 2022 Jun 8;3(2):e147. doi: 10.1002/mco2.147. eCollection 2022 Jun. MedComm (2020). 2022. PMID: 35702353 Free PMC article. Review.
-
The Expanding Therapeutic Perspective of CCR5 Blockade.Front Immunol. 2018 Jan 12;8:1981. doi: 10.3389/fimmu.2017.01981. eCollection 2017. Front Immunol. 2018. PMID: 29375583 Free PMC article. Review.
-
The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer.Biomolecules. 2019 Sep 9;9(9):464. doi: 10.3390/biom9090464. Biomolecules. 2019. PMID: 31505877 Free PMC article.
-
Identification of key immune genes of osteoporosis based on bioinformatics and machine learning.Front Endocrinol (Lausanne). 2023 Jun 7;14:1118886. doi: 10.3389/fendo.2023.1118886. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37361541 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
